secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001213900-26-022718
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial signs exclusive AD04 collaboration framework with Molteni for Europe; potential $60M in milestones and royalties
--------------------------------------------------------------------------------

- Collaboration framework with Molteni Farmaceutici for exclusive AD04 commercialization in Europe; definitive agreement pending.
- Total potential aggregate value from royalties (high single to low double digits) and milestones estimated at nearly $60M.
- Molteni granted exclusivity for due diligence; upfront and milestone payments expected upon final agreement.
- AD04 is a genotype-driven Alcohol Use Disorder therapy; company also advancing US partner discussions.
- Special meeting on Feb 26 lacked quorum; company must call new meeting every 90 days until warrant approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026022718/0001213900-26-022718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026022718/ea0279472-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-022718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer